Nothing Special   »   [go: up one dir, main page]

Dedeurwaerdere et al., 2009 - Google Patents

In-vivo imaging characteristics of two fluorinated flumazenil radiotracers in the rat

Dedeurwaerdere et al., 2009

View PDF
Document ID
7854161656775971997
Author
Dedeurwaerdere S
Gregoire M
Vivash L
Roselt P
Binns D
Fookes C
Greguric I
Pham T
Loc’h C
Katsifis A
Hicks R
O’Brien T
Myers D
Publication year
Publication venue
European journal of nuclear medicine and molecular imaging

External Links

Snippet

Purpose [11 C] Flumazenil shows promise as a clinical and research PET radiotracer to image changes in GABA A central benzodiazepine receptor (cBZR), but its widespread use has been limited by practical limitations of [11 C]. This study evaluated the imaging …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0493—Steroids, e.g. cholesterol, testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0474—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0476—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from monodendate ligands, e.g. sestamibi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins

Similar Documents

Publication Publication Date Title
O’Donoghue et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu (II)-diacetyl-bis (N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models
Moresco et al. In vivo imaging of adenosine A 2A receptors in rat and primate brain using [11 C] SCH442416
Pratt et al. Simultaneous quantitative imaging of two PET radiotracers via the detection of positron–electron annihilation and prompt gamma emissions
Jahan et al. Decreased defluorination using the novel beta-cell imaging agent [18 F] FE-DTBZ-d4 in pigs examined by PET
Kolthammer et al. PET imaging of hepatocellular carcinoma with 18 F-fluoroethylcholine and 11 C-choline
Lindner et al. Radiosynthesis of [18F] SiFA lin-TATE for clinical neuroendocrine tumor positron emission tomography
Hesse et al. Imaging of the brain serotonin transporters (SERT) with 18 F-labelled fluoromethyl-McN5652 and PET in humans
Michelhaugh et al. Assessment of tryptophan uptake and kinetics using 1-(2-18F-fluoroethyl)-L-tryptophan and α-11C-methyl-L-tryptophan PET imaging in mice implanted with patient-derived brain tumor xenografts
Ghosh et al. Dealing with PET radiometabolites
JP5709841B2 (en) Labeled molecular imaging agent, production method and use method
Lohith et al. Comparison of two PET radioligands,[11C] FPEB and [11C] SP203, for quantification of metabotropic glutamate receptor 5 in human brain
Dedeurwaerdere et al. In-vivo imaging characteristics of two fluorinated flumazenil radiotracers in the rat
Dubois et al. [18 F] EF3 is not superior to [18 F] FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model
Wang et al. An in vivo molecular imaging probe 18 F-Annexin B1 for apoptosis detection by PET/CT: preparation and preliminary evaluation
Green et al. Radiosynthesis of no-carrier-added meta-[124 I] iodobenzylguanidine for PET imaging of metastatic neuroblastoma
Kristensen et al. In vivo imaging in drug discovery
Liu et al. PET imaging of brain astrocytoma with 1-11 C-acetate
Yuan et al. Synthesis and characterization of [18 F] JNJ-46356479 as the first 18 F-labeled PET imaging ligand for metabotropic glutamate receptor 2
Yuan et al. Targeting phosphatidylethanolamine with fluorine-18 labeled small molecule probe for apoptosis imaging
Wooten et al. An in vivo comparison of cis-and trans-[18F] mefway in the nonhuman primate
Li et al. A bis-boron boramino acid PET tracer for brain tumor diagnosis
Callaghan et al. Comparison of in vivo binding properties of the 18-kDa translocator protein (TSPO) ligands [18 F] PBR102 and [18 F] PBR111 in a model of excitotoxin-induced neuroinflammation
Schirmer et al. 18F-fluorodeoxyglucose-positron emission tomography: a new explorative perspective
Bremner et al. Quantitation of benzodiazepine receptor binding with PET [11C] iomazenil and SPECT [123I] iomazenil: preliminary results of a direct comparison in healthy human subjects
Sandell et al. PET examination of [11C] 5-methyl-6-nitroquipazine, a radioligand for visualization of the serotonin transporter